A Multi-Arm, Open Label, Phase II Trial of WP1066 and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Latest Information Update: 18 Sep 2024
At a glance
- Drugs WP 1066 (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 16 Sep 2024 According to a Moleculin Biotech media release, the company participates in the virtual investor What this Means segment , Wally Klemp, CEO of Moleculin, discusses the Companys recent update on the Phase 2 clinical trial of STAT3 inhibitor in combination with radiation for the treatment of glioblastoma
- 09 Sep 2024 According to a Moleculin Biotech media release, study is being conducted under Northwestern University's Investigative New Drug application (IND) which cross references the Company's own IND, which received clearance from the U.S. Food and Drug Administration (FDA) in April 2022. This trial is funded by the National Institutes of Health (NIH) and BrainUp, a non-profit organization dedicated to bringing awareness to brain cancer.
- 09 Sep 2024 According to a Moleculin Biotech media release, company announced the enrollment and treatment of patients in an Investigator-initiated Phase 2 study evaluating WP1066 in combination with radiation therapy for the treatment of adults with glioblastoma (NU 21C06).